Evaluation of potential neurotrophic agents, such as blood-brain-barrier-permeable small molecules, which ideally could be modified to target the neuronal populations affected by PD (e.g., selective uptake by TH-positive neurons) using our protocol would facilitate the development of such a therapy. This evidence concerns the gene TH and Parkinson disease.